Log In
Print
BCIQ
Print
Print this Print this
 

VX-661

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionSmall molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector
Molecular Target Cystic fibrosis transmembrane conductance regulator (CFTR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF); Treat cystic fibrosis (CF) in combination with Kalydeco ivacaftor in patients with 2 copies of the delta F508 CF transmembrane conductance regulator (CFTR) mutation; Treat cystic fibrosis (CF) in patients with 2 copies of the delta F508 CFTR mutation
Regulatory Designation U.S. - Breakthrough Therapy (Treat cystic fibrosis (CF) in combination with Kalydeco ivacaftor in patients with 2 copies of the delta F508 CF transmembrane conductance regulator (CFTR) mutation)
Partner Royalty Pharma

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,300.0M

$3,300.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today